Beyond the needle: The future of intratumoral therapy

November 5, 2026 |

1 min read |

Jennifer C. Smith-Parker, BioSpace Insights

In this episode of Denatured, you’ll hear from from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anticancer immunity from a local injection, and redefine a foundational platform in immuno-oncology.

> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Watch on YouTube

In this episode of Denatured, you’ll listen to Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak,
president, CEO and board director at Candel Therapeutics. We investigate how intratumoral therapies can generate systemic antitumor immune responses from a localized injection, advancing a foundational platform in immuno-oncology.

Host

⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Lewis Bender, President & CEO, Intensity Therapeutics

Paul-Peter Tak, President, CEO and Board Director, Candel Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Podcasts BioSpace Insights Denatured Clinical research Healthcare Immuno-oncology Cancer

Jennifer C. Smith-Parker

Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.

BioSpace Insights

The BioSpace Insights teams performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.